🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Health Concern

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million new cases per year. Notably increased rates are reported in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the reality of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

One new antibiotic, also known as Nuzolvence, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in close succession. This treatment, which is also used to treat UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Outcomes and Global Access

Based on data detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which uses an injection and a pill. The research enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have shared positive views. Access to a single-dose, oral treatment such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered crucial to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.